Perspectives in Medical Research

Volume: 11 Issue: 3

  • Open Access
  • Systematic Review

Efficacy of anti-obesity agents: a systematic review and network meta-analysis of randomized controlled trials

1 , 1 , ​✉ 2 , 3

1 Resident, Department of Pharmacology, Smt. NHL Municipal Medical College, Ahmedabad, Ahmedabad, Gujarat, India
2 Assistant professor, Department of Pharmacology, Smt. NHL Municipal Medical College,, Ahmedabad, Gujarat, India
3 Professor and Head, Department of Pharmacology, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India
*Corresponding Author: Shah Karan Bhavesh, Assistant professor, Department of Pharmacology, Smt. NHL Municipal Medical College,, Ahmedabad, Gujarat, India
E-MAIL: [email protected]

Year: 2023, Page: 6-19, Doi: https://doi.org/10.47799/pimr.1103.03

Received: Oct. 18, 2023 Accepted: Dec. 13, 2023 Published: Dec. 13, 2023

Abstract

Background: To conduct a network meta-analysis comparing the safety and efficacy of five anti-obesity drugs approved by the United States Food and Drug Administration (US FDA)-Bupropion/Naltrexone combination (BUP/NLX), Liraglutide (LIRA), Orlistat (ORLI), Phentiramine/Topiramate combination (PHEN/TPM) and Simaglutide (SGT) vs placebo.
Methods: The study's eligibility criteria include randomized controlled trials (RCTs) with a focus on obese patients receiving BUP/NLX or LIRA or ORLI or PHEN/TPM or SGT versus placebo. We conducted a comprehensive search of electronic databases (PubMed, Embase, Cochrane Library, and Scopus) to identify relevant randomized controlled trials published, with no restrictions on the publication language or year. Three reviewers independently screened the studies, extracted data, and assessed the risk of bias using the Cochrane Risk of Bias tool. Bucher's and Bayesian Meta-regression Simulation Method were used for indirect head-to-head comparison between various active drugs. RevMan Version 5.4® along with A Network Meta- Analysis Toolkit by Cochrane Methods were used. p-value less than 0.05 was considered significant.
Results: Total 28 studies were included in this meta-analysis. PHEN/TPM combination exhibited (odds ratio :0.568, p value <0.001, cl 95%) ORLI (odds ratio: 0.889, p value <0.001, cl 95%), SGT (odds ratio: 0.922, p value <0.001, cl 95%). BUP/NLX combination exhibited a high (odds ratio: 4.61, p value <0.001, cl 95%) LIRA displayed the lowest (odds ratio: 1.109, p value <0.001, cl 95%). Network meta-analysis revealed. BUP/NLX combination exhibited highest Efficacy. ORLI found as safest among the evaluated drugs. SGT had significant likelihood of adverse events (odds ratio = 1.328, p-value<0.0001, Cl 95%) compared to ORLI (odds ratio = 0.138, p-value<0.0001, Cl 95%), BUP/NLX (odds ratio = 0.197, p-value<0.0001, cl 95%), and LIRA (odds ratio = 0.456, p-value < 0.001, Cl 95%), PHEN/TPM (odds ratio = 0.456, p-value<0.0001, Cl 95%).
Discussion: These findings have important clinical implications for the management of obesity. The BUP/NLX , LIRA , and SGT can be considered as effective treatment options for weight reduction. However, healthcare providers need to carefully consider the safety profiles and potential side-effects of these medications when making treatment decisions. The study relied on aggregated data, which might introduce bias. High attrition rates and heterogeneity among studies limit the findings. It only compared common gastrointestinal side effects and didn't use the GRADE approach for evidence quality.
Conclusion: Study provides evidence supporting the efficacy of anti-obesity medications compared to placebo. BUP/NLX combination, LIRA, and SGT emerged as the most effective agents, considering safety profile. Findings can guide clinicians about options for obesity management.
Study Registration: The study is registered with PROSPERO (CRD42023465989).

Keywords: Anti-obesity Agents, Obesity Management, Network Meta-analysis

References

  1. American Medical Association 2013. Proceedings of the 2013 Annual Meeting of the House of Delegates: AMA Adopts New Policies on Second Day of Voting at Annual Meeting.

  2. Stevens, G A, Singh, G M, Lu, Y, Danaei, G, Lin, J K & Finucane, M M . 2012. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr 10:22.

  3. Ng, Marie, Fleming, Tom, Robinson, Margaret, Thomson, Blake, Graetz, Nicholas, Margono, Christopher, Mullany, Erin C, Biryukov, Stan, Abbafati, Cristiana & Abera, Semaw Ferede . 2014. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. The lancet 384(9945):766–781.

  4. Wang, Youfa, Beydoun, May A, Liang, Lan, Caballero, Benjamin & Kumanyika, Shiriki K . 2008. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity 16(10):2323–2330.

  5. Kelly, T, Yang, W, Chen, C-S, Reynolds, K & He, J . 2005. Global burden of obesity in 2005 and projections to 2030. Int J Obes 32(9):1431–1438.

  6. Hu, F B . 2008. Obesity Epidemiology. (pp. 412-487) Oxford; New York: Oxford University Press

  7. Ornellas, Tehane & Chavez, Benjamin . 2011. Naltrexone SR/Bupropion SR (Contrave): a new approach to weight loss in obese adults. Pharmacy and Therapeutics 36(5):255.

  8. Shaefer Jr, Charles F, Kushner, Pamela & Aguilar, Richard . 2015. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate Medicine 127(8):818–826.

  9. Bansal, AB & Khalili, Y Al . 2023. Orlistat . Treasure Island (FL): StatPearls Publishing

  10. Lonneman, Jr David J, Rey, Jose A & McKee, Brian D . 2013. Phentermine/Topiramate extended-release capsules (qsymia) for weight loss. Pharmacy and Therapeutics 38(8):446–52.

  11. Apovian, Caroline M, Aronne, Louis, Rubino, Domenica, Still, Christopher, Wyatt, Holly, Burns, Colleen, Kim, Dennis, Dunayevich, Eduardo & Group, COR-II Study . 2013. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) Obesity 21(5):935–943.

  12. Hollander, P, Gupta, A K, Plodkowski, R, Greenway, F, Bays, H, Burns, C, Klassen, P, Fujioka, K & Group[, COR-Diabetes Study . 2013. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. Diabetes Care 36(12):4022–4029.

  13. Greenway, F L, Fujioka, K, Plodkowski, R A, Mudaliar, S, Guttadauria, M, Erickson, J, Kim, D D, Dunayevich, E & Group, COR-I Study . 2010. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled. Lancet 376(9750).

  14. Wadden, T A, Foreyt, J P, Foster, G D, Hill, J O, Klein, S, Neil, O&apos;, Perri, P M, Pi-Sunyer, M G, Rock, F X, Erickson, C L, Maier, J S, Kim, H N, Dunayevich, D D & E . 2011. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 19(1):110–120.

  15. Roux, Le CW, Fils-Aimé, N, Camacho, F, Gould, E & Barakat, M . 2022. The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. eClinical Medicine 49:1014–36.

  16. Rubino, D, Abrahamsson, N, Davies, M, Hesse, D, Greenway, F L, Jensen, C, Lingvay, I, Mosenzon, O, Rosenstock, J, Rubio, M A, Rudofsky, G, Tadayon, S, Wadden, T A & Dicker, D . 2021. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 325(14):1414–1425.

  17. Wilding, Jph, Batterham, R L, Calanna, S, Davies, M, Van Gaal, L F & Lingvay, I . 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine 384(11).

  18. Wadden, T A, Bailey, T S, Billings, L K, Davies, M, Frias, J P, Koroleva, A, Lingvay, I, Neil, O&apos;, Rubino, P M, Skovgaard, D M, Wallenstein, D Sor & Garvey, WT . 2021. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA 325(14):1403–1413.

  19. Davies, M, Færch, L, Jeppesen, O K, Pakseresht, A, Pedersen, S D, Perreault, L, Rosenstock, J, Shimomura, I, Viljoen, A & Wadden, T A . 2021. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971–984.

  20. Garvey, W T, Batterham, R L, Bhatta, M, Buscemi, S, Christensen, L N, Frias, J P, Jódar, E, Kandler, K, Rigas, G, Wadden, T A & Wharton, S . 2022. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28(10):2083–2091.

  21. Gadde, K M, Garvey, W T, Peterson, C A, Schwiers, M L & Najarian, T . 2011. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) Obesity 20(2):330–372.

  22. Hsia, D S, Gosselin, N H, Williams, J, Farhat, N, Marier, J F, Shih, W, Peterson, C & Siegel, R . 2020. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity. Diabetes Obes Metab 22(4):480–491.

  23. Allison, D B, Gadde, K M, Garvey, W T, Peterson, C A, Schwiers, M L & Najarian, T . 2011. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) Obesity 20(2):330–372.

  24. Garvey, W T . 2013. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opinion on Drug Safety 12(5):741–56.

  25. Chanoine, J P, Hampl, S, Jensen, C, Boldrin, M & Hauptman, J . 2005. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293(23):2873–83.

  26. Syed, A H, Meraj, A, Bhandari, L, Khan, F, Shaikh, A, Baig, K & Kumar, B . 2020. Coparision of Efficacy and Safety of Orlistat vs Placebo in Obese Patients in Pakistan. Cureus 12(8):e9775.

  27. Rössner, S, Sjöström, L, Noack, R, Meinders, A E & Noseda, G . 2000. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 8(1):49–61.

  28. Kelley, D E, Bray, G A, Pi-Sunyer, F X, Klein, S, Hill, J, Miles, J & Hollander, P . 2002. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 25(6):1033–1041.

  29. Miles, J M, Leiter, L, Hollander, P, Wadden, T, Anderson, J W, Doyle, M, Foreyt, J, Aronne, L & Klein, S . 2002. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25(7):1123–1131.

  30. Hanefeld, M & Sachse, G . 2002. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 4(6):415–438.

  31. Davidson, M H, Hauptman, J, Digirolamo, M, Foreyt, J P, Halsted, C H, Heber, D, Heimburger, D C, Lucas, C P, Robbins, D C, Chung, J & Heymsfield, S B . 1999. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281(3):235–277.

  32. Lindgärde, F . 2000. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 248(3):245–54.

  33. Krempf, M, Louvet, J P, Allanic, H, Miloradovich, T, Joubert, J M & Attali, J R . 2003. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord 27(5):591–598.

  34. O'Neil, PM, Smith, S R, Weissman, N J, Fidler, M C, Sanchez, M, Zhang, J, Raether, B, Anderson, C M & Shanahan, W R . 2012. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 20(7):1426–1436.

  35. Swinburn, B A, Carey, D, Hills, A P, Hooper, M, Marks, S, Proietto, J, Strauss, B J, Sullivan, D, Welborn, T A & Id, Caterson . 2005. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab 7(3):254–62.

  36. Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David CW, Le Roux, Carel W, Violante Ortiz, Rafael & Jensen, Christine Bj∅rn . 2015. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 373(1):11–22.

  37. Halawi, Houssam, Khemani, Disha, Eckert, Deborah, O'Neill, Jessica, Kadouh, Hoda, Grothe, Karen, Clark, Matthew M, Burton, Duane D, Vella, Adrian & Acosta, Andres . 2017. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. The Lancet Gastroenterology &amp; Hepatology 2(12):890–899.

  38. Davies, Melanie J, Bergenstal, Richard, Bode, Bruce, Kushner, Robert F, Lewin, Andrew, Skj∅th, Trine Vang, Andreasen, Arne Haahr, Jensen, Christine Bj∅rn, DeFronzo, Ralph A & Group, NN8022-1922 Study . 2015. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. Jama 314(7):687–699.

  39. Astrup, A, Carraro, R, Finer, N, Harper, A, Kunesova, M & Lean, Mej . 2011. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity 36(6):843–54.

  40. Singh, Awadhesh Kumar & Singh, Ritu . 2020. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Review of Clinical Pharmacology 13(1):53–64.

  41. Cichoń, Katarzyna, Chyćko, Ma\lgorzata, Czarnota, Julia, Kromer, Agata, Zapa\la, Magdalena Alicja, Środoń, Agnieszka, Wilk, Joanna, Cholewa, Ma\lgorzata Maria, Gawryś, Agnieszka & \Lapaj, Monika . 2023. Evaluation of the effectiveness and safety of anti-obesity drugs-an update on the current state of knowledge on available and investigational drugs. Journal of Education, Health and Sport 35(1):94–112.

  42. Calderon, G, Gonzalez-Izundegui, D & Shan, K L . 2022. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Int J Obes 46:555–563.

  43. Lin, Qiucen, Xue, Yan, Zou, Huimin, Ruan, Zhen & Hu, Carolina Oi Lam Ung &amp; Hao . 2022. Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology 15:1461–1469.

  44. Viner, R M, Hsia, Y, Tomsic, T & Wong, Ick . 2009. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obesity Reviews 11(8):593–602.

  45. Reddy, Lalita Prasad & Isaacs, Diana . 2015. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in context 4.

  46. Filippatos, T D, Derdemezis, C S, Gazi, I F, Nakou, E S, Mikhailidis, D P & Elisaf, M S . Orlistat-associated adverse effects and drug interactions: a critical review. Drug Safety 53–65.

  47. Tak, Young Jin & Lee, Sang Yeoup . 2021. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Current obesity reports 10:14–30.

  48. Patel, Priya N, Fox, Claudia K, Bensignor, Megan O & Bomberg, Eric M . 2023. Weight Loss From Combination Anti-Obesity Medication Regimens Can Approach that Achieved From Bariatric Surgery. JCEM Case Reports 1(1):luac038.

  49. Atlas, Steven J., Kim, Kim, Beinfeld, Michael, Lancaster, Victoria, Nhan, Emily, Lien, Pei-Wei, Shah, Kavi, Touchette, David R., Moradi, Amir, Rind, David M., Pearson, Steven D. & Beaudoin, Frank L. . 2022. Medications for Obesity Management: Effectiveness and Value; Evidence Report.

  50. Smith, Steven M, Meyer, Melissa & Trinkley, Katy E . 2013. Phentermine/topiramate for the treatment of obesity. Annals of Pharmacotherapy 47(3):340–349.

Cite this article

Prajapati NB, Mehta YD, Bhavesh SK, Malhotra SD. Efficacy of anti-obesity agents: a systematic review and network meta-analysis of randomized controlled trials. Perspectives in Medical Research. 2023;11(3):6-19 DOI: 10.47799/pimr.1103.03

Views
332
Downloads
72
Citations

Related Articles

A case report of KIMURA’S DISEASE with NASAL SEPTUM PRESENTATION

​✉ 1 , 2 , 3

Views: 173

View Article

Tuberculosis in geriatric patients: a cross-sectional study from tertiary care hospital in Maharashtra

1 , 2 , 3 , 4 , ​✉ 5

Views: 197

View Article

A prospective study on lung parenchymal changes in ingestional poisoning

1 , 2 , ​✉ 3

Views: 196

View Article

Assessment of awareness and attitude o f medical students about physicians’ participation in capital punishments in India — a cross-sectional study

​✉ 1 , 2

Views: 292

View Article

Preterm Retinopathy of Prematurity and risk factors from a tertiary health care unit: A descriptive study

1 , 2 , 3 , ​✉ 1 , 4 , 1 , 5 , 6

Views: 265

View Article